Neurocrine's total assets for Q3 2024 were $3.54B, an increase of 6.96% from the previous quarter. NBIX total liabilities were $816.10M for the fiscal quarter, a 2.55% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.